Targeting alternative splicing as a new cancer immunotherapy-phosphorylation of serine arginine-rich splicing factor (SRSF1) by SR protein kinase 1 (SRPK1) regulates alternative splicing of PD1 to generate a soluble antagonistic isoform that prevents T cell exhaustion. (2023)
Attributed to:
Role of heparin binding growth factors in O.viverrini induced Cholangiocarcinoma (O-CCA) development, progression and angiogenesis
funded by
Newton Fund
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1007/s00262-023-03534-z
PubMed Identifier: 37973660
Publication URI: http://europepmc.org/abstract/MED/37973660
Type: Journal Article/Review
Volume: 72
Parent Publication: Cancer immunology, immunotherapy : CII
Issue: 12
ISSN: 0340-7004